COVID-19 not expected to 'significantly delay' Genfit's phase 3 NASH readout

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Mar 31, 2020 at 11:22 AM.

  1. cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    32,746
    Likes Received:
    3
    via Genfit has told investors that it does not expect the COVID-19 pandemic to “significantly delay” the unblinding of its phase 3 nonalcoholic steatohepatitis (NASH) data. The database was locked at the end of February but will only be unblinded after the FDA has provided feedback.

    article source